B+
Bull case
20%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
SABS
SAB BiotherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
SAB-142 remains the key value driver, with a registrational Phase 2b SAFEGUARD program, a reported year-end 2026 enrollment objective, a potential 2027 topline readout, and a manufacturing agreement with Emergent that could support future clinical and commercial supply. The PRISE-hATG grant broadens the clinical opportunity.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.7.
What can break
Clinical efficacy, safety, regulatory, and trial-execution outcomes remain binary and could materially impair valuation.
Momentum
12
Value
43
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.25 · Bull $6.50 · Bear $1.75Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $11.75
Why
Momentum12 · Δ7d -6.4
Value43 · Δ7d -0.2
Sentiment75 · Δ7d -0.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -0.7.
Contradictions & invalidation
- • Clinical efficacy, safety, regulatory, and trial-execution outcomes remain binary and could materially impair valuation.
- • Peer comparisons are loose and analyst coverage is limited.
- • The company remains clinical-stage and event-driven.
Catalyst clock
2026-08-06
Q2 2026 post-earnings evidence remains unresolved
Lead driver: Sentiment · See AI snapshot
Momentum
12
8% active weight
Current posture
7d trendSoftening
Δ7d
-6.4
Δ21d
-13.1
Value
43
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.4
Sentiment
75
45% active weight
Current posture
7d trendImproving
Δ7d
-0.7
Δ21d
+12.0
Why this grade
Composite grade C. Momentum 11.9 / Value 43.4 / Sentiment 75.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$258.4M
Beta
0.59
Shares Out
90.99M
P/E (TTM) · Derived
12.9
P/S (TTM)
1552.31
P/FCF (TTM) · Derived
-2.93
Rev YoY
-100.0%
EPS YoY
-74.1%
Gross Margin
-2647.6%
Op Margin
-37656.5%
Net Debt
-$90.64M
Current Ratio
9.22
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data